Nanoparticle-delivered RNA interference drug stops head and neck cancer growth

Apr 06, 2012

(Phys.org) -- A nanoparticle drug delivery vehicle for small interfering RNA molecules (siRNA), that is already being tested in human clinical trials, now shows promise for the treatment of head and neck cancer. Dong Shin, of Emory University, and Mark E. Davis, of the Nanosystems Biology Cancer Center at the California Institute of Technology, led this study. The results were published in the Journal of Controlled Release.

Drugs based on siRNA technology are designed to turn off the production of specific proteins that are critically involved in a disease such as cancer. While a significant body of evidence has shown this approach to targeting critical disease pathways can be highly effective, siRNA molecules themselves do not survive in the blood stream. Dr. Davis and his colleagues have long been leaders in the effort to use tumor-targeted nanoparticles to protect siRNAs from degradation and deliver them to where they are needed in the body.

In this study Dr. Davis's group, which had previously developed a nanoparticle that encapsulates a siRNA agent aimed at a protein known as RRM2, has teamed up with Dr. Shin's group to evaluate the effectiveness of these particles in head and neck cancer. RRM2, when over expressed in these tumor types, plays an active role in tumor progression and in the development of . Initial tests on head and neck tumor cells growing in culture showed that this construct was taken up by the , and as a result growth of the cells was inhibited substantially. The investigators obtained similar results when they tested the drug on cultured non-small cell .

Based on these findings, the researchers tested the siRNA-loaded nanoparticle in a mouse model of human . One intravenous injection of the drug shut down production of RRM2 for at least 10 days, with the nanoparticle being present in the tumor for three days. Four injections given over 10 days triggered a substantial amount of tumor cell death and significantly reduced tumor progression. The researchers note that they did not observe any adverse effects or changes in body weight during the course of therapy. They also showed that the drug had no effect on RRM2 production in the liver.

This work, which is detailed in a paper titled, "Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth," was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer.

Explore further: Nanocontainers for nanocargo: Delivering genes and proteins for cellular imaging, genetic medicine and cancer therapy

More information: View abstract here.

Related Stories

Pack 'Em In -- Gold Nanoparticles Improve Gene Regulation

Feb 23, 2009

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes ...

Polymeric nanoparticles attack head and neck cancer

Jul 15, 2011

Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. ...

Recommended for you

Scientists grow a new challenger to graphene

1 hour ago

A team of researchers from the University of Southampton's Optoelectronics Research Centre (ORC) has developed a new way to fabricate a potential challenger to graphene.

Nanotubes help healing hearts keep the beat

1 hour ago

(Phys.org) —Carbon nanotubes serve as bridges that allow electrical signals to pass unhindered through new pediatric heart-defect patches invented at Rice University and Texas Children's Hospital.

Engineers show light can play seesaw at the nanoscale

22 hours ago

University of Minnesota electrical engineering researchers have developed a unique nanoscale device that for the first time demonstrates mechanical transportation of light. The discovery could have major ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Au-Pu
not rated yet Apr 07, 2012
Will this same system work on other tumours? In other words can we manufacture nano particles that are tumour specific.
If so this could be a really important piece of work.